Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT06660654
A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThe purpose of this research is to learn more about and investigational drug called raludotatug deruxtecan, hereafter referred to as D-DXd. it is being studies to see if it is effective, tolerable...
-
NCT06238479
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationYou are being invited to take part in this study because you have been diagnosed with a type of cancer that may express a protein called nectin-4, which LY4101174 is designed to treat and you have...
-
NCT06307795
A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThis is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in...
-
NCT06172478
A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThe purpose of this study is to learn more about an investigational drug called patritumab deruxtecan (also known as HER3-DXd or U3-1402), also referred to as “study drug” or “study treatment”...
-
NCT05176483
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationYou are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this...
-
NCT05914116
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: MultitherapeuticResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThe main goal of this study is to test whether the study drug is safe and tolerable in patients with advanced/unresectable, or metastatic solid tumors (including small cell lung cancer, non-small cell...
-
NCT05498428
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe investigational anti-cancer drugs being studied are called amivantamab (JNJ-61186372) and lazertinib (JNJ-73841937). They are being developed for the treatment of locally advanced or metastatic (i...